A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer

Novel treatments are needed in anal cancer. An important percentage of patients with locally
advanced anal cancer will have persistent loco-regional disease or develop systemic
metastases. Virtually all cases of anal cancer are related to infection by HPV. Anal cancer
cells infected with HPV have the tumor associated antigen HPV E7. ADXS11-001 causes antigen
presenting cells to be stimulated to facilitate immune cells to attack cancer cells
expressing HPV E7. ADXS11-001, at the phase II dose of 1x109 CFU, has been shown to be safe
in patients with advanced cervical cancer which also is caused by HPV infection. Anti-tumor
activity and safety have been demonstrated in cervical cancer to single agent ADXS11-001 and
the combination of ADXS11-001 and cisplatin chemotherapy. Data presented at ASCO 2012
ADXS11-001 is currently being evaluated in women in the United States with cervical
intraepithelial neoplasia. Radiation may augment the activity of ADXS11-001 increasing the
exposure of tumor related antigens thereby increasing the chance for loco-regional disease
eradication and preventing systemic recurrence. Therefore, ADXS11-001 may increase complete
response, prevent recurrence disease and increase disease-free and overall survival in anal
cancer. This protocol will develop sufficient preliminary safety and efficacy data to
facilitate the investigation of ADXS11-001 in anal cancer within "NRG", the newly formed
cooperative group based on the merger of the RTOG, NSABP and GOG.

As described above, Phase I studies and preliminary data from phase II studies have
demonstrated that ADXS11-001, 1x109 CFU, can be safely administered as a single agent and in
combination with chemotherapy. For example in over 200 patients treated at the dose of
1x109CFU there have been no cases of severe listeria bacteremia or grade 3 cardiopulmonary
toxicity. However, since ADXS11-001 has not previously been administered with radiation, the
primary objective of this study will be to establish the safety of the addition of ADXS11-001
to chemoradiation for anal cancer. The following schedules will be assessed.

• Treatment Schedule: The first dose will be given 10-14 days prior to the initiation of
chemoradiation. The 2nd-4th dosages of ADXS11-001will not be until after completion of all
chemoradiation. The second dosage of ADXS11-001 will not be administered until a minimum of
10 days after completion of chemoradiation, ANC > 1,000 cells/mm3, serum creatinine < 1.5
mg/dl and all toxicities from chemoradiation have resolved to grade 2 or less. The subsequent
third and fourth treatment with of ADXS11 will be administered at 28 day intervals. This will
provide the needed safety data to evaluate Treatment Schedule #2.

Standard treatment with mitomycin, 5-FU and radiation for anal cancer has substantial
toxicity. In RTOG 9811, 74% of patients had grade 3/4 nonhematologic toxicity and 61% of
patients had grade 3 or grade 4 hematologic toxicity from this regimen. Therefore, the
toxicities of standard chemoradiation with mitomycin, 5-FU and radiation are well above the
conventionally accepted parameters in a phase I study even prior to adding ADXS11-001.
However, it is critical that the addition of ADXS-11-001 does not compromise the delivery of
potentially curative standard chemoradiation for anal cancer.

Inclusion Criteria:

3.1.1 Histologically-proven, invasive primary squamous, basaloid, or cloacogenic carcinoma
of the anal canal; 3.1.2 AJCC 2009 TN Stage: T1N1-N3, T2(< 4cm)N1-N3, T2(> 4cm)N0,T3N0-3,
T4N0-3;based upon the following minimum diagnostic workup: 3.1.2.1 History/physical
examination within 14 days prior to registration; 3.1.2.2 Within 42 days prior to
registration, the patient must have an anal examination by any of the following:
colonoscopy, sigmoidoscopy, or rigid proctoscopy, with documentation of primary anal lesion
size, distance from anal verge.

3.1.3 Groin examination within 42 days prior to registration with documentation of any
groin adenopathy and lymphadenopathy (location: right vs. left; medial vs. lateral; mobile
vs. fixed; and size); 3.1.4 X-ray (PA and lateral), CT scan, or PET/CT scan of the chest
within 42 days prior to registration; 3.1.5 CT scan, MRI, or PET/CT of the abdomen and
pelvis within 42 days prior to registration; 3.1.6 Zubrod Performance Status 0-1; 3.1.7 Age
≥ 18; 3.1.8 Laboratory data obtained ≤ 14 days prior to registration on study, with
adequate bone marrow, hepatic and renal function defined as follows:

- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3;

- Platelets ≥ 100,000 cells/mm3;

- Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve
Hgb ≥ 8.0 g/dl is acceptable.);

- Serum creatinine ≤ 1.5 mg/dl;

- Bilirubin < 1.4mg/dl;

- ALT/AST < 3 x ULN;

- Negative serum pregnancy test for women of child-bearing potential; 3.1.9 Women of
childbearing potential and male participants must agree to use a 2 forms of medically
effective means of birth control (such as a condom and spermicide) throughout their
participation in the treatment phase of the study and for 90 days post last dose of
study drug.

3.1.10 Patients must sign a study-specific informed consent prior to study entry.

3.1.11 Patients with a history of clinically significant pulmonary disease must have PFTs
demonstrating a DLCO ≥ 40%. This testing is considered standard of care prior to mitomycin,
5-FU and radiation.

3.1.12 Patients with a history of clinically significant cardiac disease must have a LVEF ≥
30% by ECHO. (MUGA scan may also be used to determine LVEF) This testing is considered
standard of care prior to mitomycin, 5-FU and radiation.

3.1.13 Patients must be able to swallow pills.

Exclusion Criteria:

3.2.1 Prior invasive malignancy (except non-melanomatous skin cancer), unless disease free
for a minimum of 2 years; 3.2.2 Prior systemic chemotherapy for anal cancer; 3.2.3 Prior
allergic reaction to the study drugs involved in this protocol. 3.2.4 Prior radiotherapy to
the pelvis that would result in overlap of radiation therapy fields; 3.2.5 Severe, active
co-morbidity, defined as follows: 3.2.5.1 Patients with uncontrolled intercurrent illness
including, but not limited to ongoing or active infection, symptomatic congestive heart
failure, unstable angina pectoris and cardiac arrhythmia are ineligible. Furthermore,
patients with unstable angina and/or congestive heart failure requiring hospitalization
within the past 6 months are ineligible; 3.2.5.2 Patients with active infection requiring
systemic therapy (oral or IV) or those currently receiving antibiotics that cannot
discontinue prior to dosing are ineligible.

3.2.5.3 Transmural myocardial infarction within the last 6 months; 3.2.5.4 Acute bacterial
or fungal infection requiring intravenous antibiotics at the time of registration; 3.2.5.5
Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring
hospitalization or precluding study therapy at the time of registration; 3.2.5.6 Hepatic
insufficiency resulting in clinical jaundice and/or coagulation defects; 3.2.6 Patients
known to be seropositive for HIV and/or active hepatitis, even if liver function studies
are in the eligible range.

3.2.7 Other immunocompromised status (e.g., organ transplant or chronic glucocorticoid
use).If patient has diagnosis of immunodeficiency, is dependent on or has received systemic
steroids therapy or any form of immunosuppressive therapy within 7 days prior to the first
dose of ADXS11-001 they are ineligible. Topical corticosteroid or occasional inhaled
corticosteroids are allowed.

3.2.8 Women who are pregnant or lactating are ineligible because the treatment involved in
this study may be significantly teratogenic and there is the potential for transmission of
listeria to the infant.

3.2.9 Patients allergic to or with a sensitivity to penicillin, ampicillin,
trimethoprim-sulfa and quinolones (including history of rash or anaphylaxis).

3.2.10 Patients allergic to naproxen. 3.2.11 Patients receiving oral or IV antibiotics
3.2.12 Patients with a prior history of a splenectomy and/or sickle cell trait/disease
3.2.13 Patient has implanted medical device(s) that pose a high risk for colonization
and/or cannot be easily removed (e.g., prosthetic joints, artificial heart valves,
pacemakers, orthopedic screw(s), metal plate(s), bone graft(s), or other exogenous
implant(s)). NOTE: More common devices and prosthetics which include arterial and venous
stents, dental and breast implants and venous access devices (e.g. Port-a-Cath or Mediport)
are permitted. Sponsor must be contacted prior to consenting any subject who has any other
device and/or implant. Site is required to submit to BrUOG ALL surgical implants patient
has ever had in their medical history and ALL surgeries regardless of link to this cancer
diagnosis.

3.2.14 Patients who are receiving or may receive future treatment with PI3K or TNFα
inhibitors. To be confirmed by treating medical oncologist in writing 3.2.15 Has undergone
a major surgery, including surgery for a new artificial implant and/or device, within 6
weeks prior to the initiation of ADXS11-001 treatment. NOTE: if patient underwent surgery >
6 weeks from start of ADSX11-001, all toxicities and/or complications must have recovered
to baseline or Grade 1 prior to the initiation of ADXS11-001 study therapy.

3.2.16 Patient not being willing to have new infusion line placed for each infusion of
ADXS11-001 as existing or newly placed central venous catheter or infusion ports are not
allowed to be used for ADXS11-001 administration. Must be confirmed as discussed with
patient and that they agreed.

3.2.17 Patient not willing to comply with requirement of central venous catheter or
infusion port must not be used for 72 hours following the completion of the ADXS11-001
infusion and the patient receives the first post-treatment dose of oral antibiotics. Must
be confirmed as discussed with patient and that they agreed.

3.2.18 Live vaccines within 30 days prior to the first dose of trial treatment and while
participating in the trial. Examples of live vaccines include, but are not limited to, the
following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid
(oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus
vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist®) are live
attenuated vaccines and are not allowed. All recent vaccines (within 30 days) to be listed
on conmed log 3.2.19 Patient has a history of listeriosis or prior ADXS11-001 therapy.